MedTrace Logo

Efficacy and Safety of Danzhen

NCT02645370 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3300

Last updated 2016-01-01

No results posted yet for this study

Summary

The purpose is to evaluate the effectiveness and safety profile of Danzhen for the prophylaxis of migraine in a "real-world" setting.

Conditions

Interventions

DRUG

Danzhen

DRUG

Topiramate

Sponsors & Collaborators

  • Ecion Pharmaceutical CO..LTD

    collaborator UNKNOWN

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Gang Zhao, MD · Xijing Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2017-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02645370 on ClinicalTrials.gov